DHR · Danaher Corp /De/
$215.71
+0.35 (+0.16%)
At close · Aug 27
Market Cap
$151.51B
Shares
702.99M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$24.57B
+2.9%
FY2025
Net Income
$3.61B
-7.3%
FY2025
Gross Margin
59.11%
-0.4pp
FY2025
Operating Margin
19.09%
-1.3pp
FY2025
Diluted EPS
$5.05
-4.5%
FY2025
Operating Cash Flow
$6.42B
-4.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $25.11B | $24.57B | $23.88B | $23.89B | $26.64B | $24.8B | $22.28B | $17.91B | $19.89B | $18.33B | $16.88B | $14.43B | $12.87B | $18.28B | $18.26B | $16.09B | $12.55B | $10.52B | $12.7B | $11.03B | |
| $10.42B | $10.05B | $9.67B | $9.86B | $10.46B | $9.56B | $9.81B | $7.93B | $7.54B | $6.95B | $7.55B | $6.66B | $6.02B | $8.94B | $8.85B | $7.91B | $6.15B | $5.45B | $6.76B | $5.99B | |
| $14.69B | $14.52B | $14.21B | $14.03B | $16.19B | $15.24B | $12.48B | $9.98B | $9.51B | $8.57B | $9.33B | $7.77B | $6.85B | $9.34B | $9.41B | $8.18B | $6.4B | $5.07B | $5.94B | — | |
| — | 59.11% | 59.5% | 58.74% | 60.76% | 61.44% | 55.98% | 55.74% | 47.78% | 46.76% | 55.29% | 53.84% | 53.23% | 51.1% | 51.56% | 50.82% | 51.03% | 48.21% | 46.78% | — | |
| $1.62B | $1.6B | $1.58B | $1.5B | $1.53B | $1.5B | $1.35B | $1.13B | $1.06B | $956.4M | $975.1M | $861.4M | $769.4M | $1.1B | $1.14B | $1.02B | $774M | $600.27M | $725.44M | $601.42M | |
| $7.95B | $8.24B | $7.76B | $7.33B | $7.12B | $6.82B | $6.9B | $5.59B | $5.39B | $5.04B | $5.62B | $4.75B | $4.04B | $5.12B | $5.18B | $4.61B | $3.6B | $3.12B | $3.35B | $2.71B | |
| $1.76B | $1.7B | $1.63B | $1.49B | $1.43B | $1.39B | $1.14B | $625M | $616M | $579M | $583M | $397M | $269M | $339M | $342M | $284M | $199M | $156M | $145M | — | |
| — | — | — | $2.17B | $2.13B | $2.06B | $1.78B | $1.19B | $1.18B | $1.12B | $1.13B | $880.8M | $718.1M | $850.6M | $839.8M | $635M | $388.3M | $331.8M | $339.3M | — | |
| — | — | — | — | — | — | — | — | $70M | $159.1M | $152.4M | $97.5M | $102.3M | — | — | — | — | $46M | — | — | |
| $10.01B | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $9.64B | $10.83B | $9.29B | |
| $5.13B | $4.69B | $4.86B | $5.2B | $7.54B | $6.38B | $4.23B | $3.27B | $3.06B | $2.57B | $2.74B | $2.16B | $2.05B | $3.12B | $3.17B | $2.62B | $2.05B | $1.44B | $1.87B | $1.74B | |
| — | 19.09% | 20.37% | 21.77% | 28.29% | 25.71% | 18.99% | 18.25% | 15.36% | 14.03% | 16.2% | 14.98% | 15.89% | 17.07% | 17.33% | 16.27% | 16.33% | 13.69% | 14.72% | 15.79% | |
| — | — | — | $7.37B | $9.67B | $8.44B | $6.01B | $4.46B | $4.23B | $3.69B | $3.86B | $3.04B | $2.76B | $3.97B | $4B | $3.25B | $2.44B | $1.77B | $2.21B | — | |
| $292M | $265M | $278M | $286M | $204M | $231M | $275M | $108M | $137M | $140.1M | $184.4M | $139.8M | $94.7M | $141.2M | $157.5M | $141.6M | $117.1M | $118.65M | $130.17M | $109.7M | |
| $104M | $30M | $117M | $303M | $41M | $11M | $71M | $139M | $9M | $7.5M | $200K | $4.6M | $13.3M | $5.7M | $3.2M | $5.1M | $6.1M | $5.03M | $10M | $6.09M | |
| -$177M | -$222M | -$56M | -$175M | -$227M | $450M | $494M | $12M | $35M | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | $0 | $0 | $69.9M | $66.8M | $22.8M | — | — | — | |
| -$198M | -$248M | -$57M | -$182M | -$271M | $401M | $18M | $0 | — | — | — | — | — | — | — | — | — | — | — | — | |
| $4.76B | $4.23B | $4.65B | $5.04B | $7.15B | $6.51B | $4.5B | $3.31B | $2.96B | $2.54B | $2.61B | $2.04B | $2.09B | $3.42B | $3.01B | $2.45B | $2.23B | $1.33B | $1.75B | $1.64B | |
| $772M | $633M | $747M | $823M | $818M | $1.06B | $849M | $873M | $556M | $371M | $457.9M | $292.7M | $447.5M | $825.7M | $711.5M | $512.5M | $511.4M | $239.02M | $431.68M | $423.1M | |
| $4B | $3.61B | $3.9B | $4.76B | $7.21B | $6.43B | $3.65B | $3.01B | $2.65B | $2.49B | $2.55B | $3.36B | $2.6B | $2.7B | $2.39B | $2.17B | $1.79B | $1.15B | $1.32B | $1.37B | |
| — | 14.71% | 16.33% | 19.94% | 27.06% | 25.94% | 16.36% | 16.79% | 13.33% | 13.6% | 15.13% | 23.26% | 20.19% | 14.74% | 13.1% | 13.5% | 14.29% | 10.95% | 10.38% | 12.42% | |
| — | $3.61B | $3.9B | $4.74B | $7.1B | $6.27B | $3.51B | $2.94B | $2.65B | $2.49B | — | — | — | — | — | — | $1.79B | $1.15B | $1.32B | — | |
| $3.78B | $6.63B | $2.43B | $4.91B | $5.36B | $5.77B | $6.35B | $2.73B | $2.01B | $3.52B | $1.86B | $2.48B | $950.2M | $2.97B | $2.37B | $1.79B | $1.79B | — | — | — | |
| USD/shares | $5.65 | $5.07 | $5.33 | $6.44 | $9.80 | $8.77 | $4.41 | $3.64 | $3.35 | $3.17 | $3.27 | $4.26 | $3.28 | $3.43 | $3.06 | $2.85 | $2.43 | $1.60 | $1.83 | $3.90 |
| USD/shares | $5.64 | $5.05G | $5.29 | $6.38 | $9.66 | $8.61 | $4.34 | $3.59 | $3.32 | $3.13 | $3.24 | $4.20 | $3.22 | $3.37 | $2.98 | $2.76 | $2.34 | $1.53 | $1.76 | $3.71 |
| shares | — | 712.7M | 731M | 736.5M | 725.1M | 714.6M | 796.59M | 806.52M | 790.28M | 784.86M | 779.67M | 787.46M | 792.08M | 785.09M | 782.16M | 762.75M | 736.81M | 723.65M | 720.48M | 351.06M |
| shares | — | 716.1M | 737.2M | 743.1M | 737.1M | 736.8M | 810.69M | 818.36M | 801.11M | 796.48M | 789.37M | 799.19M | 807.76M | 802.01M | 804.38M | 790.95M | 770.76M | 757.43M | 757.71M | 371.63M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $9.91B in buybacks, $7.33B in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
6.92×
Peer median 6.27×
EV/EBIT
33.88×
Peer median 29.16×
P/E (TTM)
38.21×
Peer median 32.23×
Peer medians compare against the 12 similar-size Diagnostics & Research companies (of 46 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Diagnostics Segment | $9,941,000,000 | $9,787,000,000 | $9,577,000,000 | — | — | — | — | — |
| Life Sciences Segment | $7,334,000,000 | $7,329,000,000 | $7,141,000,000 | — | — | — | — | — |
| Biotechnology Segment | $7,293,000,000 | $6,759,000,000 | $7,172,000,000 | — | — | — | — | — |
| Biotechnology | — | — | — | $8,758,000,000 | $8,570,000,000 | $5,276,000,000 | — | — |
| Diagnostics | — | — | — | $10,849,000,000 | $9,844,000,000 | $7,403,000,000 | $6,561,000,000 | $6,258,000,000 |
| Environmental Applied Solutions | — | — | — | — | — | $4,305,000,000 | $4,399,000,000 | $4,320,000,000 |
| Life Sciences | — | — | — | $7,036,000,000 | $6,388,000,000 | $5,300,000,000 | $6,951,000,000 | $6,471,000,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| North America | $10,356,000,000 | $10,295,000,000 | $9,961,000,000 | $11,730,000,000 | $9,798,000,000 | $9,011,000,000 | $7,012,000,000 | $6,470,000,000 |
| High Growth Markets | $7,022,000,000 | $6,870,000,000 | $7,191,000,000 | $7,709,000,000 | $7,770,000,000 | $6,651,000,000 | $5,730,000,000 | $5,443,000,000 |
| Western Europe | $5,938,000,000 | $5,457,000,000 | $5,468,000,000 | $5,859,000,000 | $5,877,000,000 | $5,323,000,000 | $4,057,000,000 | $4,061,000,000 |
| Other Developed Markets | $1,252,000,000 | $1,253,000,000 | $1,270,000,000 | $1,345,000,000 | $1,357,000,000 | $1,299,000,000 | $1,112,000,000 | $1,075,000,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Contract with Customer Measurement Recurring | $20,127,000,000 | $19,366,000,000 | $18,682,000,000 | $20,876,000,000 | $19,135,000,000 | — | — | — |
| Revenue from Contract with Customer Measurement Nonrecurring | $4,441,000,000 | $4,509,000,000 | $5,208,000,000 | $5,767,000,000 | $5,667,000,000 | — | — | — |
| Analytical and Physical Instrumentation | — | — | — | — | — | $2,443,000,000 | $2,464,000,000 | $2,437,000,000 |
| Product Identification | — | — | — | — | — | $1,862,000,000 | $1,935,000,000 | $1,926,000,000 |
| Research and Medical Products | — | — | — | — | — | $17,979,000,000 | $13,512,000,000 | $12,686,000,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Diagnostics Segment | $2,650,000,000 | $2,625,000,000 | $2,406,000,000 | — | — | — | — | — |
| Biotechnology Segment | $1,864,000,000 | $1,685,000,000 | $1,909,000,000 | — | — | — | — | — |
| Life Sciences Segment | $520,000,000 | $879,000,000 | $1,209,000,000 | — | — | — | — | — |
| Biotechnology | — | $1,685,000,000 | $1,909,000,000 | $3,008,000,000 | $3,074,000,000 | $1,082,000,000 | — | — |
| Diagnostics | — | $2,625,000,000 | $2,406,000,000 | $3,436,000,000 | $2,313,000,000 | $1,538,000,000 | $1,134,000,000 | $1,074,000,000 |
| Environmental Applied Solutions | — | — | — | $1,135,000,000 | $1,054,000,000 | $979,000,000 | $1,052,000,000 | $988,000,000 |
| Life Sciences | — | $879,000,000 | $1,209,000,000 | $1,414,000,000 | $1,293,000,000 | $972,000,000 | $1,401,000,000 | $1,229,000,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Diagnostics Segment | 26.7% | 26.8% | 25.1% | — | — | — | — | — |
| Life Sciences Segment | 7.1% | 12% | 16.9% | — | — | — | — | — |
| Biotechnology Segment | 25.6% | 24.9% | 26.6% | — | — | — | — | — |
| Biotechnology | — | — | — | 34.3% | 35.9% | 20.5% | — | — |
| Diagnostics | — | — | — | 31.7% | 23.5% | 20.8% | 17.3% | 17.2% |
| Environmental Applied Solutions | — | — | — | — | — | 22.7% | 23.9% | 22.9% |
| Life Sciences | — | — | — | 20.1% | 20.2% | 18.3% | 20.2% | 19% |
Key facts
CIK
313616
CUSIP
235851102
13F (30d)
1483 filings
1448 filers
Visit website
Investor relations